Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits Price Target Forecast with 34.06% Profit: QuantWave Analysis

May 03, 2023
ELI LILLY AND COMPANY's stock has successfully reached the price target forecasted by QuantWave, resulting in a significant profit of 34.06%. The forecast signal was given on February 24, 2023, with the stock trading at $316.26 and a predicted long direction. On May 3, 2023, the stock price hit $423.98, meeting the forecasted target.

This achievement highlights the accuracy and effectiveness of QuantWave's analytics in predicting stock movements. The market analysis indicates that factors such as positive clinical trial results, successful product launches, and overall market sentiment towards the pharmaceutical industry have contributed to ELI LILLY AND COMPANY's stock performance.

QuantWave, an automated forecasting platform, provides users with predictions for a wide range of stocks, offering opportunities for potential profits. For investors looking to enhance their understanding of the investment strategy behind QuantWave, QuantSchool offers comprehensive educational resources. QuantSchool delves into the key principles for generating consistent income using the QuantWave forecasting system.

Find out how the ELI LILLY AND COMPANY rate is expected to change

Get Forecast for LLY
There are no comments yet. Be the first to leave a comment
If you want to leave a comment, then you need Login or Register





Other news for LLY

LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....

LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....

LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....



Related news

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits QuantWave's Price Target Forecast with a Profit of 17.34%  ~1 min.

On January 23, 2025, QuantWave, the automated forecasting platform, issued a short forecast signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at 692.73 $....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 16.89% Profit  ~1 min.

QuantWave's forecast for REGENERON PHARMACEUTICALS, INC. proved accurate as the stock reached the predicted target price on April 4, 2025....

REGNMay 9, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 25.34% Profit Margin: A Victory for QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit margin of 25.34%....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with Profit of 15.56%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave on April 4, 2025....

REGNApril 8, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target with 20% Profit: QuantWave Analysis  ~1 min.

In a recent success for QuantWave's forecasting platform, the stock of REGENERON PHARMACEUTICALS, INC. has hit its price target with a 20% profit margin....